Market Spotlight: Hodgkin’s Lymphoma, Pharma Intelligence

Market Spotlight: Hodgkin’s Lymphoma, Pharma Intelligence

  • May 2021 •
  • 44 pages •
  • Report ID: 5780051 •
  • Format: PDF
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
The analyst estimates that in 2019, there were 80,800 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028.
In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.
The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/TNFRSF8, microtubules (tubulin), DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.
The greatest proportion of the industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II, with no drugs in Phase III.
Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral, intratumoral, and subcutaneous formulations.
The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 51 trials.
Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin’s lymphoma, followed by Bristol Myers Squibb.